By otakuyassine3@gmail.com 
Shares of STAAR Surgical (NASDAQ:STAA – Get Free Report) have earned an average rating of “Hold” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $25.29.
STAA has been the topic of several research reports. Mizuho downgraded shares of STAAR Surgical from an “outperform” rating to a “neutral” rating and decreased their price target for the company from $45.00 to $17.00 in a research note on Wednesday, February 12th. Canaccord Genuity Group lowered their target price on shares of STAAR Surgical from $28.00 to $17.00 and set a “hold” rating on the stock in a report on Thursday, February 13th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, February 27th. Stifel Nicolaus lowered their price objective on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Finally, Jefferies Financial Group downgraded STAAR Surgical from a “buy” rating to a “hold” rating in a research report on Wednesday, February 12th.
View Our Latest Report on STAAR Surgical
STAAR Surgical Trading Down 4.3 %
Shares of NASDAQ STAA opened at $16.52 on Wednesday. The business’s 50 day moving average is $17.40 and its 200-day moving average is $23.74. The firm has a market cap of $814.85 million, a P/E ratio of -40.29 and a beta of 0.75. STAAR Surgical has a 1-year low of $13.50 and a 1-year high of $49.86.
Insider Buying and Selling at STAAR Surgical
In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 8,221 shares of the stock in a transaction on Thursday, January 16th. The stock was purchased at an average price of $21.50 per share, with a total value of $176,751.50. Following the completion of the purchase, the insider now owns 10,878,007 shares in the company, valued at $233,877,150.50. The trade was a 0.08 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In the last quarter, insiders have acquired 1,750,802 shares of company stock valued at $28,584,295. 1.00% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On STAAR Surgical
Hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC lifted its stake in STAAR Surgical by 123.1% in the 1st quarter. SG Americas Securities LLC now owns 49,072 shares of the medical instruments supplier’s stock valued at $865,000 after purchasing an additional 27,075 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of STAAR Surgical by 4,086.0% during the first quarter. GAMMA Investing LLC now owns 14,651 shares of the medical instruments supplier’s stock worth $258,000 after buying an additional 14,301 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of STAAR Surgical by 13.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 110,506 shares of the medical instruments supplier’s stock valued at $2,684,000 after acquiring an additional 13,075 shares during the last quarter. Voloridge Investment Management LLC lifted its stake in shares of STAAR Surgical by 9.4% in the 4th quarter. Voloridge Investment Management LLC now owns 296,256 shares of the medical instruments supplier’s stock valued at $7,196,000 after acquiring an additional 25,350 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of STAAR Surgical by 81.3% during the 4th quarter. Squarepoint Ops LLC now owns 117,074 shares of the medical instruments supplier’s stock valued at $2,844,000 after acquiring an additional 52,488 shares in the last quarter. 96.70% of the stock is currently owned by institutional investors and hedge funds.
STAAR Surgical Company Profile
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.
Featured Articles
Receive News & Ratings for STAAR Surgical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for STAAR Surgical and related companies with MarketBeat.com’s FREE daily email newsletter.